Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 10, 2026

Cisco Announces New Silicon One G300, Advanced Systems and Optics to Power and Scale AI Data Centers for the Agentic Era

View original at finance.yahoo.com
Cisco Announces New Silicon One G300, Advanced Systems and Optics to Power and Scale AI Data Centers for the Agentic Era New G300-powered Cisco N9000 and 8000 systems, advanced optics and management upgrades deliver hyperscale-level performance, reliability and efficiency for all AI network builders…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Hyperscale and neocloud customers need networking that matches GPU density, and G300 silicon enhances this with industry-leading buffers, power efficiency, and 1.6T port density

    80% confidence
  • 100% liquid cooled systems enable nearly 70% energy efficiency improvement and deliver the same bandwidth in a single system that would previously have required 6 prior generation systems

    80% confidence
  • Cisco N9000 series powered by G300 Silicon One for breakthrough 1.6T scale-out performance dramatically expands what's possible for AI infrastructure

    80% confidence
  • 800G LPO reduces optical module power consumption by 50% compared to retimed optical modules and overall switch power by 30%

    80% confidence
  • At AI-factory scale, performance is defined by how tightly the network and data layer work together

    80% confidence
  • AI at scale demands open, standards-based networking that customers can deploy with confidence across diverse environments

    80% confidence
  • Back-end scale-out networks will rapidly move to 1.6T and be a key driver to push the Ethernet data center switch market above $100B a year

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com